Avid Bioservices Stock (NASDAQ:CDMO)
Previous Close
$12.16
52W Range
$4.07 - $12.48
50D Avg
$10.91
200D Avg
$8.86
Market Cap
$779.62M
Avg Vol (3M)
$1.68M
Beta
1.41
Div Yield
-
CDMO Company Profile
Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. The company produces monoclonal antibodies and recombinant proteins; and offers services, including CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support. It also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, testing, and characterization. The company serves biotechnology and biopharmaceutical industries. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is headquartered in Tustin, California.
CDMO Performance
Peer Comparison
Ticker | Company |
---|---|
ANAB | AnaptysBio, Inc. |
DICE | DICE Therapeutics, Inc. |
IDYA | IDEAYA Biosciences, Inc. |
DYN | Dyne Therapeutics, Inc. |
KALV | KalVista Pharmaceuticals, Inc. |
LRMR | Larimar Therapeutics, Inc. |
MLYS | Mineralys Therapeutics, Inc. |
EWTX | Edgewise Therapeutics, Inc. |
MGTX | MeiraGTx Holdings plc |
IMCR | Immunocore Holdings plc |
CERE | Cerevel Therapeutics Holdings, Inc. |
ACRV | Acrivon Therapeutics, Inc. Common Stock |
KDNY | Chinook Therapeutics, Inc. |
KROS | Keros Therapeutics, Inc. |
CRNX | Crinetics Pharmaceuticals, Inc. |
ANEB | Anebulo Pharmaceuticals, Inc. |
ADAG | Adagene Inc. |
CYTK | Cytokinetics, Incorporated |
KRTX | Karuna Therapeutics, Inc. |
FIXX | Q32 Bio Inc. |
BCYC | Bicycle Therapeutics plc |
LYRA | Lyra Therapeutics, Inc. |
MIRM | Mirum Pharmaceuticals, Inc. |